Evaluasi Penggunaan Obat Kemoterapi Pada Pasien Kanker Payudara Di RSUP Fatmawati Periode Februari 2021
##plugins.themes.academic_pro.article.sidebar##
##plugins.themes.academic_pro.article.main##
Abstract
Breast cancer is a malignancy that originates from glandular cells, glandular ducts and breast supporting tissues excluding breast skin (PerMenKes, 2018). Treatment of breast cancer can use chemotherapy drugs alone or a combination of several chemotherapy drugs. Chemotherapy drugs are given in stages, generally for 6-8 cycles so that the curative effect is achieved and the side effects received by the patient can be reduced. This study aims to evaluate the use of chemotherapy drugs in breast cancer patients at Fatmawati General Hospital for the period of February 2021. This research is a non-experimental type of research with a retrospective evaluative descriptive design from patient medical records and analyzed descriptively quantitatively. This research method used a descriptive design with retrospective observational data collection, namely by collecting medical record data from breast cancer patients, this study used purposive sampling and obtained 34 patients who met the inclusion criteria. The study showed that the most age of breast cancer patients who underwent chemotherapy at Fatmawati General Hospital in February 2021 were patients with an age range of 36-45 years, with 18 patients (52.94%), the most common type of chemotherapy drug regimen used was the CAF regimen (Cyclophosphamide + Doxorubicin + 5 FU) in 8 patients (23.53%), therapy with the CAF regimen was given starting from the patient's age in the late adult range (46-55 years) until past the late elderly (> 65 years), drug therapy with the CAF regimen as the first-line standard (first line) is the most widely used with doses according to the National Guidelines for Medical Services for Management of Breast Cancer and a deviation between 1-13%, other regimens a combination of Carboplatin and Paclitaxel in 5 patients (14.71%) with doses and deviations ranging from 0-79% more lower than the literature.
Key words: Breast Cancer, Chemotherapy, Chemotherapy Drug Regimen, CAF, CEF
##plugins.themes.academic_pro.article.details##
References
Klaus Hendrich, Heinz Weinberger (2010). Selected Schedules in The Therapy of Malignant Tumors, 15th Edition. Page164-194.
Diedra L. Bragalone. (2012) Drug Information Handbook for Oncology A Complete Guide to Combination Chemotherapy Regimens. American Pharmacists Association. 10th Edition. Page 1441,1484-1485.
Komite Nasional Penganggulangan Kanker (2015). Panduan Nasional Penanganan Kanker Payudara, Versi 1.0. 2015, Hal. 10-11.
Nursyi, IR. (2015). Gambaran Pengetahuan dan Sikap Wanita Usia 48 – 55 Tahun Tentang Menopause di Desa Weru RT 02 RW 05 Weru Sukoharjo Tahun 2015. Fakultas Kesehatan Masyarakat; Universitas Airlangga.
Menteri Kesehatan Republik Indonesia (2016). Peraturan Menteri Kesehatan Nomor 72 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Rumah Sakit. Kemenkes RI; Jakarta.
Komite Nasional Penanggulangan Kanker Nasional (2018). Pedoman Nasional Pelayanan Kedokteran Kanker Payudara. Kemenkes RI; Jakarta.
Kemenkes RI (2018). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara. KepMenKes No. HK.01.07/MenKes /414/2018.
National Comprehensive Cancer Network (2020). Breast Cancer Invasive. NCCN Guidelines for Patients; Plymouth Meeting, PA.
Juwita Putri A., dkk. (2020) Evaluasi Penggunaan Obat Kemoterapi Pada Penderita Kanker Payudara di RSUP Dr. Soeradji Tirtonegoro Periode 2018, Pharmaceutical Journal of Islamic Pharmacy, Pharmasipha, Vol. 4, No. 2, September 2020.